Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

BMS-345541 has been used:as an IκB kinase (IKK) complex inhibitor to study its effects on the interferon-γ (IFN-γ) production by natural killer (NK) cellsas an IKK inhibitor to study its effects on the expression of eotaxin and monocyte chemoattractant protein-1 (MCP-1) mRNA in gingival fibroblastsas nuclear factor κB (NF-κB) pathway inhibitor to study its effects on tumor necrosis factor α (TNFα) production in human oral squamous carcinomacells

Biochem/physiol Actions

BMS-345541 is an IKB kinase (IKK) allosteric site inhibitor.

BMS-345541 possesses anti-inflammatory properties. It also blocks the nuclear factor κB (NF-κB)-dependent transcription of pro-inflammatory cytokines. BMS-345541 possesses anti-inflammatory activity and plays a role in arresting bone erosion in certain animal models.

Features and Benefits

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

5, 25 mg in glass bottle